JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus maintains an Overweight rating on Conmed (NYSE:CNMD) but lowers the price target from $135 to $115.

February 01, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Conmed but lowers the price target from $135 to $115.
The adjustment in price target by a major analyst like JP Morgan can influence investor sentiment. However, the maintenance of an Overweight rating suggests a continued positive outlook on the company, potentially balancing the impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100